CMVLF (Cellectis) Payments of Debt: $-17.09 Mil (TTM As of Mar. 2026)


CMVLF Cellectis SA CMVLF
60 GF Score
Price $3.47
GF Value $3.74
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cellectis Payments of Debt?

Cellectis CMVLF 60 Payments of Debt is $-17.09 Mil as of Mar. 2026. GuruFocus rates CMVLF with a GF Score™ of 60/100 and a GF Value™ of $3.74 (Fairly Valued). The stock has 4 warning signs investors should review.

Cellectis's Payments of Debt for the three months ended in Mar. 2026 was $-4.84 Mil.

Cellectis's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-17.09 Mil.

Cellectis Payments of Debt Related Terms

Cellectis Payments of Debt Historical Data

* Premium members only.

The historical data trend for Cellectis's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Payments of Debt Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.64 -12.35 -16.19 -16.06 -16.19

Cellectis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.94 -4.08 -4.10 -4.07 -4.84
CMVLF
60GF Score
Cellectis SA CMVLF
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-17.09 Mil mean?
Cellectis (CMVLF) has a Payments of Debt of $-17.09 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cellectis and its competitors.
Is Cellectis' Payments of Debt too high?
Cellectis' current Payments of Debt is $-17.09 Mil. Overall, Cellectis has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' Payments of Debt compare to VRTX and REGN?
Cellectis' Payments of Debt of $-17.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cellectis and its competitors. Cellectis's current Payments of Debt is $-17.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CMVLF) is currently considered Fairly Valued. The stock's GF Value™ is $3.74, compared to a current price of $3.47 — trading 7.2% below its estimated fair value. The current Payments of Debt is $-17.09 Mil. Cellectis' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Cellectis (CMVLF), the current Payments of Debt is $-17.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of $3.47 is trading 7.2% below its estimated GF Value™ of $3.74. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for CMVLF:

  • Payments of Debt: $-17.09 Mil
  • GF Value™: $3.74 vs. price of $3.47 (7.2% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
60GF Score

Get the complete analysis for CMVLF

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.74
GF Value